Global Search | Novartis

Hide Filters

Sort by

Relevance

Newest first

Oldest first

Showing 1213 results

Media Release / Feb 04, 2023
Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx®
In two of the largest Phase III trials conducted in hidradenitis suppurativa (HS), Cosentyx® (secukinumab) treatment response rates continued to improve beyond the primary endpoint analysis at Week…
Key Release / Feb 01, 2023
Novartis continues to grow with further core margin expansion and achieves important innovation milestones
Ad hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating income…
Key Release / Feb 01, 2023
Novartis poursuit sa croissance avec une nouvelle expansion de sa marge core et franchit des étapes importantes dans l’innovation
Annonce événementielle au sens de l’art. 53 RCExercice entier Chiffre d’affaires net en hausse de +4% (tcc1, -2% USD) et résultat opérationnel core croissant de +8% (tcc, 0% USD) Innovative…
Key Release / Feb 01, 2023
Novartis setzt Wachstumskurs mit weiterer Steigerung der Kerngewinnmarge fort und erreicht wichtige Innovations-meilensteine
Ad-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr Der Nettoumsatz stieg um +4% (kWk1, –2% USD), wobei sich das operative Kernergebnis um +8% (kWk, 0% USD) verbesserte Innovative…
Media Release / Jan 30, 2023
Sandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilar
Sandoz is seeking approval of high concentration formulation (HCF) adalimumab for use in all indications of reference medicine Upon approval, HCF formulation will offer patients enhanced yet familiar…
Media Release / Jan 24, 2023
Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio
Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from AstellasAcquiring leading global echinocandin, one of three major antifungal classes, will significantly…
Media Release / Dec 13, 2022
Novartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5
Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult paroxysmal nocturnal hemoglobinuria (PNH)…
Media Release / Dec 13, 2022
Novartis receives European Commission approval for Pluvicto® as the first targeted radioligand therapy for treatment of progressive PSMA–positive metastatic castration-resistant prostate cancer
EC approval based on results from pivotal Phase III VISION trial, in which Pluvicto® plus best standard of care (BSoC) significantly improved overall survival and radiographic progression-free…
Media Release / Dec 08, 2022
Novartis investigational iptacopan provides clinically meaningful increases in hemoglobin levels in complement-inhibitor-naïve patients with PNH
Phase III APPOINT-PNH study of investigational oral monotherapy iptacopan met its primary endpoint; second positive Phase III topline readout for iptacopan in paroxysmal nocturnal hemoglobinuria (PNH…
Media Release / Dec 06, 2022
Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy
RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer (MBC), including visceral crisis, comparing a CDK4/6 inhibitor (CDK4/6i) plus…

‹ Previous page
1
…
11
12
13
14
15
16
17
…
122
› Next page